Leila Nicolas

GO Capital SAS (GO Capital) is an independent French private equity firm founded 2003 and is headquartered in Saint-Jacques-de-la-Lande. Formerly known as Grand Ouest Gestion SAS, the firm's investors include regional and cooperative banks, Natixis and CDC PME.GO Capital is located in Rennes and focuses primarily on the northwest quarter of France, also known as Grand Ouest, which comprises the Brittany, Poitou-Charentes, Pays de la Loire and Basse Normandie regions. The firm manages the Ouest Ventures fund.

Pherecydes Pharma SA is a biotechnology company, which engages in the research and development of anti-infective therapies based on the use of bacteriophages. It develops phage treatments of bacterial infections. The company was founded by Jerome Gabard and Manuel Gea in December 2006 and is headquartered in Romainville, France.

Bayer Pharma AG engages in the development and production of prescription drugs for the treatment of cardiovascular diseases and women's illnesses, as well as special therapy in the areas of oncology, hematology, and ophthalmology. It also offers medical equipment used in diagnostic imaging with applications in the field of radiology. The company was founded on March 9, 1965 and is headquartered in Berlin, Germany.

VitaDx International SAS develops a solution for early diagnosis of bladder cancer. It offers Fluorescence, a technology that can classify cancer cells as tumorous or healthy, and machine learning, a software analysis that used a set of mathematical techniques allowing algorithms to solve problems from data without being explicitly programmed. The company was founded by Allan Rodriguez in 2013 and is headquartered in Rennes, France.

Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France.

Graftys SA designs, manufactures and markets calcium phosphate-based synthetic bone substitutes to the global orthopedic and dental surgery markets. Its research and development projects include injectable and resorbable synthetic bone substitutes, biological repair of cartilage and of the spine, as well as bone substitutes combined with pharmaceutical agents. The company was founded by Jean Marc Ferrier, Alain Valet, Jean-Michel Bouler and Aurélien Valet in September 2005 and is headquartered in Aix-en-Provence, France.

VitamFero SA engages in the manufacture of pharmaceutical products and vaccines. It develops anti-infectious vaccines, first against Apicomplexe parasites such as toxoplasmosis agent, neosporosis agent and cryptosporidiosis agent. The firm is involved in the development of anti-parasite vaccines fulfilling unmet needs essentially in veterinary health. The company was founded on November 15, 2005 by Pascal Breton and Edouard Sèche and is headquartered in Evry, France.